

Contents

	Preface	<i>XIII</i>
1	General Aspects	3
1.1	History	5
1.1.1	From Willow Bark to Salicylic Acid	5
1.1.1.1	Anti-Inflammatory and Analgesic Effects of Willow Bark and Leaves	5
1.1.1.2	Salicylates as the Active Ingredients of Willow Bark and Other Natural Sources	6
1.1.1.3	Chemical Synthesis of Salicylic Acid	6
	Summary	8
	References	8
1.1.2	Synthesis of Acetylated Salicylic Acid and First Medical Use	9
1.1.2.1	The Invention of Acetylated Salicylic Acid	9
1.1.2.2	Introduction of Acetylsalicylic Acid into the Clinics	15
	Summary	16
	References	16
1.1.3	Search for Pharmacological Modes of Action	18
1.1.3.1	Salicylates and Energy Metabolism of the Cell	18
1.1.3.2	Aspirin and Prostaglandin Formation	19
1.1.3.3	Aspirin and COX-2	21
	Summary	23
	References	23
1.1.4	Clinical Applications: A Piece of History	25
1.1.4.1	Anti-Inflammatory/Analgesic Actions	25
1.1.4.2	Antiplatelet/Antithrombotic Actions and the Bleeding Tendency	26
1.1.4.3	Aspirin and the History of Prevention of Myocardial Infarction and Stroke	27
	Summary	30
	References	30
1.1.5	Current Research Topics	32
1.1.5.1	Clinical Research	32

1.1.5.2	Basic Research	33
	Summary	39
	References	39
1.2	Chemistry	41
1.2.1	Structures and Chemical Properties of Salicylates	41
1.2.1.1	Salicin: The Natural Salicylate	41
1.2.1.2	Salicylates in Clinical Use	41
1.2.1.3	Aspirin Formulations	43
	Summary	45
	References	46
1.2.2	Determination of Salicylates	47
1.2.2.1	Gas–Liquid Chromatography	47
1.2.2.2	High-Performance Liquid Chromatography	47
1.2.2.3	Spectrophotometry	47
	Summary	49
	References	49
2	Pharmacology	51
2.1	Pharmacokinetics	54
2.1.1	Absorption and Distribution	54
2.1.1.1	Absorption and Bioavailability	54
2.1.1.2	Aspirin Formulations	57
2.1.1.3	Distribution and Plasma Levels	60
2.1.1.4	Modifying Factors	62
	Summary	63
	References	64
2.1.2	Biotransformation and Excretion	66
2.1.2.1	Aspirin Esterases	66
2.1.2.2	Biotransformations of Salicylic Acid	70
2.1.2.3	Excretion of Salicylates	71
	Summary	72
	References	72
2.2	Cellular Modes of Action	75
2.2.1	Inhibition of Cyclooxygenases	76
2.2.1.1	COX-Isoforms, Substrates, and Regulation	76
2.2.1.2	Inhibition/Modulation of Cyclooxygenases by Aspirin	78
2.2.1.3	The Different Pharmacology of Aspirin and NSAIDs	82
2.2.1.4	Modulation of COX-2 Gene Expression	84

2.2.1.5	Further Actions of Salicylates on Lipid Mediators	85
	Summary	85
	References	86
2.2.2	COX-Independent Actions of Aspirin on Cell Function	89
2.2.2.1	Salicylates in the Plant Kingdom	89
2.2.2.2	Transacetylation Actions by Aspirin	89
2.2.2.3	Aspirin and Nitric Oxide Formation	91
2.2.2.4	Salicylates and Kinases	92
2.2.2.5	Salicylates and Transcription Factors	96
	Summary	98
	References	99
2.2.3	Energy Metabolism	101
2.2.3.1	Different Pharmacodynamics of Aspirin and Salicylates	101
2.2.3.2	Fatty Acid β -Oxidation	102
2.2.3.3	Uncoupling of Oxidative Phosphorylation	106
2.2.3.4	Metabolic Actions of Salicylates and Reye's Syndrome	108
	Summary	109
	References	110
2.3	Actions on Organs and Tissues	113
2.3.1	Hemostasis and Thrombosis	113
2.3.1.1	General Aspects	113
2.3.1.2	Platelets	115
2.3.1.3	Endothelial Cells	123
2.3.1.4	Plasmatic Coagulation	128
2.3.1.5	Fibrinolysis	128
	Summary	129
	References	130
2.3.2	Inflammation, Pain, and Fever	136
2.3.2.1	General Aspects	136
2.3.2.2	Inflammation	137
2.3.2.3	Pain	142
2.3.2.4	Fever	147
	Summary	149
	References	150
2.3.3	Aspirin and Malignancies	153
2.3.3.1	General Aspects	153
2.3.3.2	Pathophysiology	154
2.3.3.3	Modes of Aspirin Action	156
2.3.3.4	COX-Related Actions of Aspirin	157
2.3.3.5	Non-COX-Related Antitumor Actions of Aspirin	160
	Summary	162
	References	162

3	Toxicity and Drug Safety	167
3.1	Systemic Side Effects	170
3.1.1	Acute and Chronic Toxicity	170
3.1.1.1	General Aspects	170
3.1.1.2	Pathophysiology and Clinical Symptoms of Acute Overdosing	172
3.1.1.3	Treatment	175
3.1.1.4	Habituatation	177
	Summary	177
	References	178
3.1.2	Bleeding Time and Bleeding Risk	180
3.1.2.1	Aspirin and Bleeding Time	180
3.1.2.2	Mode of Aspirin Action	181
3.1.2.3	Aspirin-Related Bleeding Risk in Long-Term Prevention and Acute Surgical Interventions	184
3.1.2.4	Prevention and Treatment of Bleedings	186
	Summary	187
	References	188
3.1.3	Safety Pharmacology in Particular Life Situations	191
3.1.3.1	Pregnancy and Fetal Development	191
3.1.3.2	The Elderly Patient	193
	Summary	195
	References	195
3.2	Organ Toxicity	198
3.2.1	Gastrointestinal (GI) Tract	198
3.2.1.1	General Aspects	198
3.2.1.2	Pathophysiology of Aspirin-Induced GI Injury	199
3.2.1.3	Mode of Aspirin Action	201
3.2.1.4	Clinical Studies	205
3.2.1.5	Aspirin and Other Drugs	209
	Summary	211
	References	211
3.2.2	Liver	216
3.2.2.1	General Aspects	216
3.2.2.2	Pathophysiology and Mode of Aspirin Action	216
3.2.2.3	Clinical Studies	217
	Summary	217
	References	218
3.2.3	Kidney	219
3.2.3.1	General Aspects	219
3.2.3.2	Analgesic Nephropathy and its Pathophysiology	219

3.2.3.3	Mode of Aspirin Action	220
3.2.3.4	Clinical Studies – Individuals without Kidney Diseases	221
3.2.3.5	Clinical Studies – Individuals with Preexisting Kidney Diseases	223
	Summary	225
	References	226
3.2.4	Audiovestibular System	228
3.2.4.1	General Aspects	228
3.2.4.2	Pathophysiology of Aspirin-Induced Hearing Loss and Tinnitus	228
3.2.4.3	Mode of Aspirin Action	228
3.2.4.4	Clinical Studies	230
	Summary	231
	References	231
3.3	Hypersensitivity to Aspirin and Reye's Syndrome	233
3.3.1	Aspirin-Exacerbated Respiratory Disease (AERD, "Aspirin-Induced Asthma")	233
3.3.1.1	History, Epidemiology, and Pathophysiology	233
3.3.1.2	Mode of Aspirin Action	237
3.3.1.3	Clinical Studies	239
3.3.1.4	Aspirin and Other Drugs	240
	Summary	240
	References	241
3.3.2	Urticaria/Angioedema and Stevens–Johnson and Lyell's Syndrome	244
3.3.2.1	Urticaria/Angioedema	244
3.3.2.2	Stevens–Johnson Syndrome and Lyell's Syndrome	245
	Summary	245
	References	245
3.3.3	Reye's Syndrome	247
3.3.3.1	Clinics, Laboratory and Morphological Findings	248
3.3.3.2	Etiology and Pathogenesis	249
3.3.3.3	Clinical Studies	252
3.3.3.4	Actual Situation	256
	Summary	258
	References	259
4	Clinical Applications of Aspirin	263
4.1	Thromboembolic Diseases	268
4.1.1	Coronary Vascular Disease	269
4.1.1.1	General Aspects	269
4.1.1.2	Thrombotic Risk and Mode of Aspirin Action	271
4.1.1.3	Clinical Trials: Primary Prevention in Apparently Healthy Individuals	275
4.1.1.4	Clinical Trials: Primary Prevention in Individuals with Vascular Risk Factors	279

4.1.1.5	Clinical Trials: Cardiovascular Prevention in Patients with Stable Angina	284
4.1.1.6	Clinical Trials: Acute Coronary Syndromes (ACS)	285
4.1.1.7	Clinical Trials: Long-Term Secondary Prevention	288
4.1.1.8	Clinical Trials: Coronary Artery Bypass Graft Surgery (CABG) and Other Surgical Interventions	291
4.1.1.9	Aspirin and Other Drugs	292
4.1.1.10	Actual Situation	297
	Summary	298
	References	299
4.1.2	Cerebrovascular Diseases	307
4.1.2.1	General Aspects	307
4.1.2.2	Thrombotic Risk and Mode of Aspirin Action	308
4.1.2.3	Clinical Trials: Primary Prevention	312
4.1.2.4	Clinical Trials: Secondary Prevention	314
4.1.2.5	Aspirin and Other Drugs	318
4.1.2.6	Actual Situation	323
	Summary	324
	References	325
4.1.3	Peripheral Arterial Disease	330
4.1.3.1	General Aspects	330
4.1.3.2	Thrombotic Risk and Mode of Aspirin Action	330
4.1.3.3	Clinical Trials: Primary Prevention	332
4.1.3.4	Clinical Trials: Secondary Prevention	334
4.1.3.5	Clinical Trials: Peripheral Transluminal Angioplasty (PTA) and Surgical Interventions	336
4.1.3.6	Aspirin and Other Drugs	337
4.1.3.7	Actual Situation	339
	Summary	339
	References	339
4.1.4	Venous Thrombosis	343
4.1.4.1	General Aspects	343
4.1.4.2	Thrombotic Risk and Mode of Aspirin Action	343
4.1.4.3	Clinical Trials: Primary Prevention	344
4.1.4.4	Clinical Trials: Secondary Prevention	348
4.1.4.5	Aspirin and Other Drugs	350
4.1.4.6	Actual Status	350
	Summary	351
	References	351
4.1.5	Preeclampsia	354
4.1.5.1	General Aspects	354
4.1.5.2	Thrombotic Risk and Mode of Aspirin Action	354
4.1.5.3	Clinical Trials: Early Studies	358
4.1.5.4	Clinical Trials: Reasons for Data Variability	359

4.1.5.5	Actual Situation	363
	Summary	364
	References	365
4.1.6	Aspirin “Resistance” (High On-Aspirin Treatment Platelet Reactivity)	369
4.1.6.1	General Aspects	369
4.1.6.2	Definition and Types of Pharmacological Aspirin “Resistance” (HTPR)	370
4.1.6.3	Detection of Aspirin “Resistance” and Possible Pitfalls in Its Determination	371
4.1.6.4	Phenotypes of Aspirin “Resistance” (HTPR)	373
4.1.6.5	Clinical Trials	379
4.1.6.6	Actual Situation	383
	Summary	383
	References	384
4.2	Pain, Fever, and Inflammatory Diseases	389
4.2.1	Analgesia and Antipyresis	390
4.2.1.1	General Aspects	390
4.2.1.2	Pain, Fever, and Mode of Analgesic/Antipyretic Aspirin Action	390
4.2.1.3	Clinical Trials	394
4.2.1.4	Aspirin and Other Drugs	397
4.2.1.5	Actual Situation	397
	Summary	397
	References	398
4.2.2	Inflammatory Diseases	401
4.2.2.1	General Aspects	401
4.2.2.2	Rheumatoid Arthritis: Pathophysiology and Mode of Aspirin Action	402
4.2.2.3	Osteoarthritis: Pathophysiology and Mode of Aspirin Action	403
4.2.2.4	Systemic Inflammatory Response Syndrome (SIRS): Pathophysiology and Mode of Aspirin Action	403
4.2.2.5	HIV: Pathophysiology and Mode of Aspirin Action	404
4.2.2.6	Clinical Trials	405
4.2.2.7	Aspirin and Other Drugs	407
4.2.2.8	Actual Situation	410
	Summary	410
	References	411
4.2.3	Kawasaki’s Disease	414
4.2.3.1	General Aspects	414
4.2.3.2	Pathophysiology and Mode of Aspirin Action	414
4.2.3.3	Clinical Trials	415
4.2.3.4	Aspirin and Other Drugs	416
4.2.3.5	Actual Situation	416
	Summary	416
	References	417

4.3	Further Potential Clinical Indications	418
4.3.1	Colorectal Cancer	418
4.3.1.1	General Aspects	418
4.3.1.2	Pathophysiology of Intestinal Neoplasias	419
4.3.1.3	Mode of Aspirin Action	419
4.3.1.4	Clinical Trials: Primary Prevention	423
4.3.1.5	Clinical Trials: Secondary Prevention	428
4.3.1.6	Aspirin, Other Drugs, and Environmental Factors	431
4.3.1.7	Actual Situation	432
	Summary	434
	References	434
4.3.2	Alzheimer's Disease	438
4.3.2.1	General Aspects	438
4.3.2.2	Pathophysiology and Mode of Aspirin Action	438
4.3.2.3	Clinical Trials	440
4.3.2.4	Aspirin and Other Drugs	444
4.3.2.5	Actual Situation	444
	Summary	444
	References	445
	Appendix 1: Abbreviations	447
	Appendix 2: Selected Clinical Trials and Their Acronyms – Only Published Trials	449
	Index	453